Treat-to-target: not as simple as it appears

Area of Science:

• Rheumatology
• Clinical Strategy
• Patient-Centered Care

Background:

• Treat-to-target (T2T) is a widely advocated strategy for rheumatoid arthritis (RA) management.
• Strong evidence supports T2T, but its universal implementation faces challenges.
• Existing T2T approaches may not suit all RA patients due to comorbidities, joint damage, or patient preferences.

Purpose of the Study:

• To critically evaluate the implementation of treat-to-target strategies in rheumatoid arthritis.
• To highlight limitations and caveats in applying universal T2T goals.
• To advocate for personalized RA care beyond standardized targets.

Main Methods:

• Review of existing literature and clinical trial data on treat-to-target in RA.
• Analysis of outcome measures, including radiographic progression, physical function, and mortality.
• Examination of treatment modalities, such as disease-modifying anti-rheumatic drugs (DMARDs) and biological agents.
• Consideration of patient-specific factors and socioeconomic influences on RA management.

Main Results:

• Remission or low disease activity targets are not universally applicable to all RA patients.
• Radiographic progression may be overemphasized compared to physical function and mortality in T2T studies.
• Methotrexate and other conventional DMARDs demonstrate effective outcomes, often comparable or superior to biological agents in clinical trials.
• Patient factors like age, education, comorbidities, and country's GDP significantly influence RA patient status and treatment response.

Conclusions:

• While T2T is appropriate for many RA patients, a one-size-fits-all approach is insufficient.
• Individualized RA treatment plans are essential, considering patient-specific factors and preferences.
• Optimizing RA care requires awareness of T2T limitations and a focus on comprehensive patient well-being.